(Albany, US), November 04, 2026 – DelveInsight’s ‘Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of IC-MPGN, historical and forecasted epidemiology, as well as the immune complex membranoproliferative glomerulonephritis market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Explore the intricate details of the Immune Complex Membranoproliferative Glomerulonephritis Market Report @ Immune Complex Membranoproliferative Glomerulonephritis Market Size
Key Takeaways from the Immune Complex Membranoproliferative Glomerulonephritis Market Report
In March 2026, Biogen and Apellis Pharmaceuticals announced a definitive agreement under which Biogen will acquire Apellis.
In February 2026, SanegeneBio announced that SGB-9768 received Orphan Drug Designation from the US FDA for IC-MPGN.
According to DelveInsight’s analysis, the IC-MPGN market size was found to be ~USD 30 million in the 7MM in 2025.
The IC-MPGN market is projected to grow at a CAGR of 26% during 2026-2036.
Among the 7MM, the US accounted for the largest IC-MPGN market size, at ~USD 20 million in 2025.
In 2025, the total number of diagnosed prevalent cases of IC-MPGN in the 7MM was about 7,000. The US accounted for the highest number, with ~3,500 cases, followed by Japan.
According to the UK registry, the minimal point prevalence is 1.3/100,000 for MPGN UK-wide.
In 2025, children accounted for only about 10% of total IC-MPGN cases in the US, while adults had a much higher prevalence, with approximately 3,400 cases.
IC-MPGN is classified as idiopathic only after an exhaustive evaluation fails to identify an underlying cause. Emerging evidence suggests that a subset of cases may be driven by dysregulation and overactivation of the alternative complement pathway.
Treatment of IC-MPGN remains largely supportive, with no universally established disease-specific standard of care. Conventional management includes RAAS blockade and immunosuppressive agents in selected patients.
The leading IC-MPGN companies include Biogen (Apellis Pharmaceuticals), Swedish Orphan Biovitrum AB, SanegeneBio, Novartis, and others.
Promising IC-MPGN therapies include Pegcetacoplan (EMPAVELI), Iptacopan (LNP023), SGB-9768, and others.
Get a Free sample for the Glomerulonephritis Market Forecast, Size & Share Analysis Report @ Glomerulonephritis Market
Immune Complex Membranoproliferative Glomerulonephritis Overview
Primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) is a rare, chronic kidney disorder that places a significant, disruptive burden on patients and their caregivers. Excessive C3 deposits are a key marker of disease activity and can lead to kidney inflammation, damage, and failure. IC-MPGN can be primary (idiopathic) or secondary to underlying conditions such as infections, autoimmune diseases, or malignancies. Patients often present with proteinuria, hematuria, hypertension, and declining kidney function, and the disease may progress to chronic kidney disease (CKD) or end-stage kidney failure if not adequately managed.
Diagnosis combines clinical evaluation, laboratory testing, and histopathological confirmation. Initial findings typically include proteinuria (often nephrotic range), microscopic hematuria, reduced kidney function, and possibly low complement levels (especially C3 and C4). Kidney biopsy is the gold standard, revealing mesangial proliferation, thickened capillary walls, and immune complex deposits. Immunofluorescence microscopy shows immunoglobulins (e.g., IgG) along with complement components, helping differentiate IC-MPGN from C3 glomerulopathy (C3G), where C3 deposition predominates. Approximately 50% of people living with C3G and primary IC-MPGN suffer kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or lifelong dialysis.
Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Segmentation in the 7MM
Total Prevalent Cases of IC-MPGN
Total Diagnosed Prevalent Cases of IC-MPGN
Gender-specific Incident Cases of IC-MPGN
Age-specific Incident Cases of IC-MPGN
Download the report to understand which factors are driving IC-MPGN epidemiology trends @ US Membranous Nephropathy Market
Immune Complex Membranoproliferative Glomerulonephritis Epidemiology Key Findings
In 2025, the total number of diagnosed prevalent cases of IC-MPGN in the 7MM was about 7,000.
In 2025, the US accounted for the highest number of diagnosed prevalent cases of IC-MPGN, with ~3,500 cases, followed by Japan.
Males represented more than 50% of total IC-MPGN cases in the US in 2025.
IC-MPGN cases are more prevalent in adults than in pediatrics.
Although the incidence of idiopathic IC-MPGN remains unknown, the estimated global annual incidence of C3G ranges from 1 to 3 cases per million individuals. Up to 30–35% of patients with C3G or idiopathic IC-MPGN develop kidney failure within 10 years of diagnosis.
Approved Therapies for Immune Complex Membranoproliferative Glomerulonephritis
Pegcetacoplan (EMPAVELI): Biogen (Apellis Pharmaceuticals) and Swedish Orphan Biovitrum A
EMPAVELI is a targeted complement component 3 (C3) therapy that regulates excessive activation of the complement cascade. It is the first and only FDA-approved treatment for pediatric (12+ years) and adult patients with primary IC-MPGN, and was approved in July 2025 to reduce proteinuria. The Phase III VALIANT study was the largest single trial in patients 12 years and older and the only one to include pediatric and adult patients with native and post-transplant kidneys. EMPAVELI demonstrated a 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits compared to placebo.
Immune Complex Membranoproliferative Glomerulonephritis Pipeline Analysis
Iptacopan (LNP023): Novartis
Iptacopan is an oral, first-in-class, small-molecule complement factor B inhibitor, currently in the Phase III APPARENT study for idiopathic IC-MPGN. According to the company’s February 2026 investor presentation, clinical trial data readout is anticipated in 2028.
SGB-9768: SanegeneBio
SGB-9768 is a GalNAc-conjugated experimental RNAi-based medicine designed to silence C3 mRNA in hepatocytes, thereby inhibiting complement activation. It is currently in Phase II studies for IC-MPGN. In a Phase I trial, a single subcutaneous dose achieved dose-dependent, significant, and sustained reduction in serum C3 and inhibition of complement pathway activity, with a favorable safety and tolerability profile. The clinical trial is ongoing in China, and the company holds global commercial rights.
Discover more about therapies set to grab major market share @ C3 Glomerulopathy Market and Complement 3 Glomerulopathy Treatment Market
Immune Complex Membranoproliferative Glomerulonephritis Market Outlook
The IC-MPGN treatment landscape is shifting from long-standing reliance on supportive care and broad immunosuppression toward mechanism-based, targeted strategies. Historically, patients were managed with renin–angiotensin system blockers, diuretics, corticosteroids, and other immunosuppressive agents. The approval of pegcetacoplan (EMPAVELI), the first targeted therapy for IC-MPGN, validated complement inhibition as a disease-modifying approach.
The pipeline is expanding with next-generation complement-targeted agents. Complement factor B inhibitors such as iptacopan represent a shift toward oral, long-term complement control, while SGB-9768, an investigational siRNA therapy, aims to lower circulating C3 levels to prevent kidney damage and slow progression. The entry of late- to mid-stage candidates is expected to intensify competition in the latter half of the forecast period. Overall, approved therapies and rising disease awareness are expected to drive steady growth in the 7MM IC-MPGN market from 2022–2036. EMPAVELI continues to elevate the standard of care, supported by over 3,000 patient-years of systemic pegcetacoplan exposure.
Immune Complex Membranoproliferative Glomerulonephritis Market Drivers
Rising prevalence and underlying conditions, such as hepatitis C, lupus nephritis, and monoclonal gammopathy
Lack of universally established disease-specific therapies, which pushes organizations to develop new treatments
Improved diagnostics and clinician awareness for distinguishing IC-MPGN from C3G, leading to earlier diagnoses and more treated patients
Immune Complex Membranoproliferative Glomerulonephritis Unmet Needs
Limited approved therapies
Distinction from C3G and underlying causes
High risk of progression to kidney failure
Diagnostic delays, and others
Immune Complex Membranoproliferative Glomerulonephritis Treatment Landscape
Treatment of IC-MPGN focuses on controlling blood pressure, reducing proteinuria, and managing cholesterol through pharmacologic interventions, lifestyle modifications, and emerging complement-targeted therapies. Medications commonly used to slow kidney damage include ACE inhibitors and ARBs, diuretics, corticosteroids and other immunosuppressive agents, and statins.
To know more about IC-MPGN companies working in the treatment market, visit @ GCC Immunosuppressive Drugs Market and Membranous Nephropathy Market
Scope of the Immune Complex Membranoproliferative Glomerulonephritis Market Report
Coverage: 7MM
Study Period: 2022-2036
Forecast Period: 2026-2036
IC-MPGN Companies: Biogen (Apellis Pharmaceuticals), Swedish Orphan Biovitrum AB, SanegeneBio, Novartis, and others
IC-MPGN Therapies: Pegcetacoplan (EMPAVELI), Iptacopan (LNP023), SGB-9768, and others
IC-MPGN Market Dynamics: market drivers and barriers
IC-MPGN Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis
IC-MPGN Unmet Needs, KOL Views, Reimbursement, Cost Assumptions and Pricing Analogues
Table of Contents
Key Insights
Report Introduction
Executive Summary
Key Events
Epidemiology and Market Methodology of IC-MPGN
IC-MPGN Market Overview at a Glance
Disease Background and Overview of IC-MPGN
Epidemiology and Patient Population of IC-MPGN
Patient Journey of IC-MPGN
Marketed Therapies
Emerging Therapies
IC-MPGN: Seven Major Market Analysis
Unmet Needs of IC-MPGN
SWOT Analysis of IC-MPGN
KOL Views of IC-MPGN
Market Access and Reimbursement of IC-MPGN
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Abhishek kumarEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market
